Abstract
Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.
Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable modified Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 10,481 patients with COVID-19 were included (22.4% aged 66 – 75 years; 38.7% female) of which 30.5% had a history of cardiac disease. Patients with heart disease were older, predominantly male and more likely to have other comorbid conditions when compared to those without. COVID-19 symptoms at presentation did not differ between these groups. Mortality was higher in patients with cardiac disease (30.3%; n=968 versus 15.7%; n=1143). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.06 [95% CI 0.98 – 1.15, p-value 0.13]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for NYHA III/IV heart failure (aRR 1.43 [95% CI 1.22 – 1.68, p-value <0.001]) and atrial fibrillation (aRR 1.14 [95% CI 1.04 – 1.24, p-value 0.01]). None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment.
Conclusion There is considerable heterogeneity in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with severe heart failure are at greatest risk of death when hospitalized with COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Dutch Heart Foundation, as a National Institute for Health Research (NIHR)/British Heart Foundation COVID-19 Flagship research programme, the EuroQol Research Foundation, Novartis Global, Amgen Europe, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland (CAPACITY-COVID) and the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation (LEOSS). Marijke Linschoten is supported by the Alexandre Suerman Stipend of the University Medical Center Utrecht. Folkert W. Asselbergs is supported by CardioVasculair Onderzoek Nederland 2015-12 eDETECT and along with Bryan Williams supported by the NIHR University College London Hospitals Biomedical Research Centre. Fleur V. Y. Tjong is supported by the NWO Rubicon grant 452019308, the Amsterdam Cardiovascular Institute MD/PhD Grant 2019-2020 and Postdoc Grant 2020. The work of Philippe Kopylov and Daria Gognieva was financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital biodesign and personalized healthcare no. 057-15-2020-926.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics entity of the lead center of CAPACITY-COVID (Medical Research Ethics Committee Utrecht) deemed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study and therefore an official approval of this study by the MREC Utrecht was not required under the WMO (reference number WAG/avd/20/010579).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.
